ADVM Adverum Biotechnologies Inc

Price (delayed)

$2.365

Market cap

$232.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.44

Enterprise value

$303.85M

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ...

Highlights
The quick ratio has grown by 36% YoY but it has contracted by 12% from the previous quarter
Adverum Biotechnologies's equity has increased by 34% YoY but it has decreased by 9% QoQ
Adverum Biotechnologies's net income has shrunk by 59% YoY and by 12% QoQ
ADVM's EPS is down by 18% YoY and by 7% QoQ

Key stats

What are the main financial stats of ADVM
Market
Shares outstanding
98.13M
Market cap
$232.07M
Enterprise value
$303.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
30.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.51
Earnings
Revenue
$7.5M
EBIT
-$137.06M
EBITDA
-$132.43M
Free cash flow
-$114.56M
Per share
EPS
-$1.44
Free cash flow per share
-$1.17
Book value per share
$3.87
Revenue per share
$0.08
TBVPS
$5.37
Balance sheet
Total assets
$526.15M
Total liabilities
$147.01M
Debt
$125.36M
Equity
$379.14M
Working capital
$365.74M
Liquidity
Debt to equity
0.33
Current ratio
18.82
Quick ratio
18.03
Net debt/EBITDA
-0.54
Margins
EBITDA margin
-1,765.8%
Gross margin
100%
Net margin
-1,842.3%
Operating margin
-1,834.2%
Efficiency
Return on assets
-27.9%
Return on equity
-32.6%
Return on invested capital
-29.4%
Return on capital employed
-27.1%
Return on sales
-1,827.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADVM stock price

How has the Adverum Biotechnologies stock price performed over time
Intraday
6.05%
1 week
5.58%
1 month
-1.46%
1 year
-78.12%
YTD
-78.18%
QTD
-32.43%

Financial performance

How have Adverum Biotechnologies's revenue and profit performed over time
Revenue
$7.5M
Gross profit
$7.5M
Operating income
-$137.57M
Net income
-$138.17M
Gross margin
100%
Net margin
-1,842.3%
Adverum Biotechnologies's operating margin has surged by 95% YoY but it has decreased by 12% QoQ
Adverum Biotechnologies's net margin has surged by 95% YoY but it has decreased by 12% QoQ
Adverum Biotechnologies's net income has shrunk by 59% YoY and by 12% QoQ
ADVM's operating income has plunged by 52% YoY and by 12% from the previous quarter

Growth

What is Adverum Biotechnologies's growth rate over time

Valuation

What is Adverum Biotechnologies stock price valuation
P/E
N/A
P/B
0.61
P/S
30.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.51
ADVM's EPS is down by 18% YoY and by 7% QoQ
The price to book (P/B) is 69% lower than the 5-year quarterly average of 1.9 and 69% lower than the last 4 quarters average of 1.9
Adverum Biotechnologies's equity has increased by 34% YoY but it has decreased by 9% QoQ
The P/S is 97% below the 5-year quarterly average of 892.3

Efficiency

How efficient is Adverum Biotechnologies business performance
ADVM's ROS has soared by 95% YoY but it is down by 12% QoQ
Adverum Biotechnologies's return on invested capital has increased by 29% YoY and by 3.9% QoQ
Adverum Biotechnologies's return on equity has increased by 14% YoY but it has decreased by 6% QoQ
The company's return on assets rose by 11% YoY

Dividends

What is ADVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADVM.

Financial health

How did Adverum Biotechnologies financials performed over time
The total assets has surged by 59% year-on-year and by 14% since the previous quarter
ADVM's current ratio is up by 42% year-on-year but it is down by 9% since the previous quarter
Adverum Biotechnologies's debt is 67% lower than its equity
Adverum Biotechnologies's equity has increased by 34% YoY but it has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.